文献速递临床试验与 GCP流行病学与生物统计

克罗恩病扩大肠系膜切除术:EXCEED研究方案——一项盲法多中心随机对照临床试验

Extended mesenteric resection in Crohn's disease: EXCEED Study Protocol-a blinded multicenter randomized controlled clinical trial (RCT).
PubMed 文献 · Trials · 2025-11-21

EXCEED研究是一项盲法多中心随机对照临床试验,纳入208例患者,比较扩大肠系膜切除术(A组)与保留肠系膜的标准切除术(B组)对克罗恩病术后复发的影响。主要终点为12个月回结肠镜检查的改良Rutgeerts评分>i2a的内镜复发。

要点

  • EXCEED研究纳入208例患者,随机分为扩大肠系膜切除组与标准切除组。
  • 主要终点为12个月回结肠镜下的内镜复发(改良Rutgeerts评分>i2a)。
  • 次要终点包括6个月和12个月临床复发及术后3年和5年复发。

核心结论

  • 该研究旨在探讨扩大肠系膜切除术对克罗恩病术后复发的影响,以填补相关文献空白。

研究设计与样本

  • 盲法多中心随机对照临床试验,纳入208例患者,按术前药物治疗类别(无、免疫治疗、生物治疗)和入组时治疗机构进行分层。
  • A组为治疗组,接受扩大肠系膜切除术;B组为对照组,接受保留大部分肠系膜的标准切除术。
  • 由于外科干预研究的性质,手术医生无法设盲。

主要发现

  • 主要终点为12个月随访回结肠镜检查的改良Rutgeerts评分>i2a的内镜复发。
  • 次要终点包括6个月和12个月临床复发以及术后3年和5年复发。
  • 三级终点包括根据蒙特利尔分型的术中疾病严重程度的影响、生物治疗对复发率的影响、根据综合并发症指数(CCI)评估的术后并发症负担、通过问卷(5Q-5D-5L和SIBDQ)评估的患者报告结局以及成本效益分析。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Crohn's disease presents a persistent challenge, particularly concerning disease recurrence in patients after previous intestinal resection. This recurrence often necessitates additional medical treatment or surgery, imposing a substantial burden on patients, healthcare systems, and society. Emerging evidence suggests that extended mesenteric excision may reduce recurrence. The EXCEED study aims to investigate the mesentery's influence on disease recurrence in Crohn's disease. METHODS/DESIGN: Blinded multicenter randomized controlled clinical trial involving 208 patients. Patients will undergo randomization into two groups: Group A, the treatment group, will receive extended mesenteric resection, while Group B, the control group, will undergo the standard resection with the mesentery largely preserved. Stratification will occur based on preoperative medicinal treatment categories (none, immunological, biological) and the treatment facility at the time of inclusion. This randomized controlled trial will incorporate blinding procedures, with the understanding that due to the nature of this interventional surgical study, the operating surgeon cannot be blinded. Primary endpoint is endoscopic signs of recurrence, defined as a modified Rutgeerts score > i2a, at the 12-month follow-up ileo-colonoscopy. Secondary endpoints include clinical recurrence at 6 and 12 months, as well as recurrence at 3 and 5 years postoperatively. Tertiary endpoints are; impact of disease severity at the time of operation, according to the Montreal classification, impact of biological treatment on recurrence rates, postoperative complications burden according to the Comprehensive Complication Index (CCI), patient reported outcome through questionnaires (5Q-5D-5L and SIBDQ) and cost-effectiveness analysis. DISCUSSION: This study addresses a critical gap in Crohn's disease literature, aiming to provide evidence on the impact of extended mesenteric excision in preventing disease recurrence, thereby contributing to enhanced patient outcomes. TRIAL REGISTRATION: ClinicalTrials.gov NCT06324838. Registered on 04/02/2024.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Bælum JK, Rosenberg J, Larsen P, et al. Extended mesenteric resection in Crohn's disease: EXCEED Study Protocol-a blinded multicenter randomized controlled clinical trial (RCT). Trials. 2025. PMID: 41272703. doi:10.1186/s13063-025-09261-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。